Berna Sahan
Berna Sahan has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
Ferda Ciftci
Ophthalmology Clinic, Batigoz Hospital, Istanbul, Turkey
2 shared publications- Asli Koskderelioglu
University of Health Sciences, Izmir Faculty of Medicine, Department of Neurology, Turkey
1 shared publication Aylin Yaba
Department of Histology and Embryology, School of Medicine, Yeditepe University, Istanbul, Turkey
1 shared publicationBayram Yilmaz
Department of Physiology, School of Medicine, Yeditepe University, Istanbul, Turkey
1 shared publicationBelkıs Ilgaz Yalvac
Department of Ophthalmology, School of Medicine, Yeditepe University, Istanbul, Turkey
1 shared publication- Ferda Çiftçi
Ophthalmology Clinic, Batigoz Hospital, Istanbul, Turkey
1 shared publication
Latest Publications
- 15 September 2025
- Published by Bozok Tip Dergisi in Bozok Tıp Dergisi
- Vol. 15 (3) , 368-373
Factors Affecting Pain Following Transepithelial Photorefractive Keratectomy for Myopia and Astigmatism
Purpose: In this study, to clarify predictive factors related to postoperative pain following T-PRK. Material and Methods: Detailed medical history was taken and ophthalmological examinations were done in all patients undergoing T-PRK. Presence of pain in the preoperative era, size of ablation during T-PRK procedure, postoperative complaints and Visual analogue scale (VAS) score were recorded on the postoperative 1st day. During evaluation of postoperative complaints, patients were asked to give a score between 1 and 10 regarding complaint severity. Patients with VAS score
- 15 September 2025
- Published by Bozok Tip Dergisi in Bozok Tıp Dergisi
- Vol. 15 (3) , 368-373
Factors Affecting Pain Following Transepithelial Photorefractive Keratectomy for Myopia and Astigmatism
Purpose: In this study, to clarify predictive factors related to postoperative pain following T-PRK. Material and Methods: Detailed medical history was taken and ophthalmological examinations were done in all patients undergoing T-PRK. Presence of pain in the preoperative era, size of ablation during T-PRK procedure, postoperative complaints and Visual analogue scale (VAS) score were recorded on the postoperative 1st day. During evaluation of postoperative complaints, patients were asked to give a score between 1 and 10 regarding complaint severity. Patients with VAS score
- Open Access
- 13 September 2023
- Published by Elsevier in Photodiagnosis and Photodynamic Therapy
- Vol. 44, 103802
The relationship between retinal neurodegenerative changes and overactive bladder syndrome in multiple sclerosis
- 13 September 2023
- Published by Elsevier in Photodiagnosis and Photodynamic Therapy
- Vol. 44, 103802
Open AccessThe relationship between retinal neurodegenerative changes and overactive bladder syndrome in multiple sclerosis
- 17 August 2022
- Published by Springer Nature in International Ophthalmology
- Vol. 43 (2) , 541-547
Trephination and silicone tube intubation in the treatment of canalicular obstruction
Purpose To evaluate the efficacy of trephination and monocanalicular/bicanalicular silicone tube use depending on the number of affected canaliculi in patients with canalicular obstruction. Methods This retrospective study included 46 eyes of 36 patients who underwent trephination and silicone tube intubation performed by a single experienced oculoplastic surgeon due to canalicular obstruction between 2005 and 2020. Monocanalicular silicone tube was applied to patients with one canalicular obstruction, and bicanalicular silicone tube was applied to those with the upper and lower canalicular involvement of the same eye. Canalicular obstructions were divided into groups according to their localization as proximal, middle, and distal. The silicone tubes were kept in place for at least 5 months after the operation, and the follow-up duration of the patients was at least 12 months. Results Twenty (55.6%) patients were female and 16 (44.4%) were male. The mean age was 15.82 ± 7.02 years in the treatment success group and 28.87 ± 12.74 years in the treatment failure group (p = 0.001). While 67.6% of the eyes in the treatment success group had monocanalicular obstruction (monocanalicular silicone tube applied), 66.7% of those in the treatment failure group had bicanalicular obstruction (bicanalicular silicone tube applied) (p = 0.049). The most common distal obstruction was seen in the treatment success group, and the least distal obstruction and the most proximal obstruction were observed in the treatment failure group (p < 0.001). The mean duration silicone tube stay was 9.37 ± 1.96 months in the treatment success group and 7.25 ± 1.42 months in the treatment failure group (p = 0.003). Conclusion We consider that trephination with the use of a monocanalicular or bicanalicular silicone tube depending on the number of affected canaliculi can be the first choice of treatment in canalicular obstruction due to its high success rate, especially in distal obstruction.
- 17 August 2022
- Published by Springer Nature in International Ophthalmology
- Vol. 43 (2) , 541-547
Trephination and silicone tube intubation in the treatment of canalicular obstruction
Purpose To evaluate the efficacy of trephination and monocanalicular/bicanalicular silicone tube use depending on the number of affected canaliculi in patients with canalicular obstruction. Methods This retrospective study included 46 eyes of 36 patients who underwent trephination and silicone tube intubation performed by a single experienced oculoplastic surgeon due to canalicular obstruction between 2005 and 2020. Monocanalicular silicone tube was applied to patients with one canalicular obstruction, and bicanalicular silicone tube was applied to those with the upper and lower canalicular involvement of the same eye. Canalicular obstructions were divided into groups according to their localization as proximal, middle, and distal. The silicone tubes were kept in place for at least 5 months after the operation, and the follow-up duration of the patients was at least 12 months. Results Twenty (55.6%) patients were female and 16 (44.4%) were male. The mean age was 15.82 ± 7.02 years in the treatment success group and 28.87 ± 12.74 years in the treatment failure group (p = 0.001). While 67.6% of the eyes in the treatment success group had monocanalicular obstruction (monocanalicular silicone tube applied), 66.7% of those in the treatment failure group had bicanalicular obstruction (bicanalicular silicone tube applied) (p = 0.049). The most common distal obstruction was seen in the treatment success group, and the least distal obstruction and the most proximal obstruction were observed in the treatment failure group (p < 0.001). The mean duration silicone tube stay was 9.37 ± 1.96 months in the treatment success group and 7.25 ± 1.42 months in the treatment failure group (p = 0.003). Conclusion We consider that trephination with the use of a monocanalicular or bicanalicular silicone tube depending on the number of affected canaliculi can be the first choice of treatment in canalicular obstruction due to its high success rate, especially in distal obstruction.
- 31 May 2021
- Published by SAGE Publications in European Journal of Ophthalmology
- Vol. 32 (3) , 1464-1468
The significance of primary monocanalicular silicone tube intubation in late surgical treatment in children
Purpose: To evaluate the effect of monocanalicular silicone tube intubation outcomes as an initial surgical treatment in children older than 1 year old with primary nasolacrimal obstruction. Methods: Probing or monocanalicular silicone tube intubation was performed as primary surgical treatment on 12–48 months old children with primary nasolacrimal obstruction. Probing was performed on 53 eyes of 43 patients and silicone tube intubation on 45 eyes of 39 patients. Treatment was considered successful after improvement in patient complaints, the presence of normal tear meniscus, and normal results of fluorescein disappearance time test. Retrospective treatment success was compared between two groups according to age groups. Results: Treatment success was 79.1% in the probing group and 92.3% in the silicone tube intubation group. The success of the treatment was evaluated separately in the groups of 12 to <24 months, 24 to <36 months, and 36 to <48 months, and although the success level of the silicone tube intubation group was consistently found to be higher, the difference was not statistically significant. Treatment success decreased statistically significantly in the probing group with increased age of the patients, especially after 24 months. There was no such statistically significant decrease in the silicone tube intubation group. Conclusion: The choice of monocanalicular silicone tube intubation for primary surgical treatment in children with primary nasolacrimal obstruction provides success without the need for repetitive surgical interventions, especially in children older than 24 months.
- 31 May 2021
- Published by SAGE Publications in European Journal of Ophthalmology
- Vol. 32 (3) , 1464-1468
The significance of primary monocanalicular silicone tube intubation in late surgical treatment in children
Purpose: To evaluate the effect of monocanalicular silicone tube intubation outcomes as an initial surgical treatment in children older than 1 year old with primary nasolacrimal obstruction. Methods: Probing or monocanalicular silicone tube intubation was performed as primary surgical treatment on 12–48 months old children with primary nasolacrimal obstruction. Probing was performed on 53 eyes of 43 patients and silicone tube intubation on 45 eyes of 39 patients. Treatment was considered successful after improvement in patient complaints, the presence of normal tear meniscus, and normal results of fluorescein disappearance time test. Retrospective treatment success was compared between two groups according to age groups. Results: Treatment success was 79.1% in the probing group and 92.3% in the silicone tube intubation group. The success of the treatment was evaluated separately in the groups of 12 to <24 months, 24 to <36 months, and 36 to <48 months, and although the success level of the silicone tube intubation group was consistently found to be higher, the difference was not statistically significant. Treatment success decreased statistically significantly in the probing group with increased age of the patients, especially after 24 months. There was no such statistically significant decrease in the silicone tube intubation group. Conclusion: The choice of monocanalicular silicone tube intubation for primary surgical treatment in children with primary nasolacrimal obstruction provides success without the need for repetitive surgical interventions, especially in children older than 24 months.
- 5 June 2019
- Published by Wolters Kluwer Health in Cornea
- Vol. 38 (9) , 1161-1168
Comparison of the Effects of Dovitinib and Bevacizumab on Reducing Neovascularization in an Experimental Rat Corneal Neovascularization Model
To compare the inhibitory effects of dovitinib and bevacizumab for treatment of corneal neovascularization (CNV). Thirty-nine adult female Sprague Dawley rats weighing 180 to 250 g were used. CNV was induced by silver nitrate in the right eye of each rat. After the chemical burn, the animals were randomized into 5 groups. Group 1 did not receive any chemical substance. Group 2 received dimethyl sulfoxide, group 3 received bevacizumab 5 mg/mL, group 4 received dovitinib 5 mg/mL, and group 5 received bevacizumab 5 mg/mL + dovitinib 5 mg/mL topically administered twice daily for 14 days. On the 14th day, slit-lamp examination was performed, and anterior segment photographs were taken. The corneal neovascular area was measured on photographs as the percentage of the cornea's total area using computer imaging analysis. The corneal sections were stained with hematoxylin and eosin for histopathological examination. A statistically significant decrease in the percentage of CNV was found in all treatment groups (group 3, group 4, and group 5) compared with the control group (group 1) (P < 0.01). A statistically significant difference in the percentage of CNV was found among group 3, group 4, and group 5 (P = 0.003). The percentage of CNV in group 4 was significantly higher than that in group 3 and group 5 (P 1 = 0.004; P 2 = 0.006). There was no statistically significant difference in the percentage of CNV between group 3 and group 5 (P = 0.228). Dovitinib is a newly developed multitargeted tyrosine kinase inhibitor. Topical administration of dovitinib effectively inhibited CNV, but this effect of dovitinib was found less than topical bevacizumab.
- 5 June 2019
- Published by Wolters Kluwer Health in Cornea
- Vol. 38 (9) , 1161-1168
Comparison of the Effects of Dovitinib and Bevacizumab on Reducing Neovascularization in an Experimental Rat Corneal Neovascularization Model
To compare the inhibitory effects of dovitinib and bevacizumab for treatment of corneal neovascularization (CNV). Thirty-nine adult female Sprague Dawley rats weighing 180 to 250 g were used. CNV was induced by silver nitrate in the right eye of each rat. After the chemical burn, the animals were randomized into 5 groups. Group 1 did not receive any chemical substance. Group 2 received dimethyl sulfoxide, group 3 received bevacizumab 5 mg/mL, group 4 received dovitinib 5 mg/mL, and group 5 received bevacizumab 5 mg/mL + dovitinib 5 mg/mL topically administered twice daily for 14 days. On the 14th day, slit-lamp examination was performed, and anterior segment photographs were taken. The corneal neovascular area was measured on photographs as the percentage of the cornea's total area using computer imaging analysis. The corneal sections were stained with hematoxylin and eosin for histopathological examination. A statistically significant decrease in the percentage of CNV was found in all treatment groups (group 3, group 4, and group 5) compared with the control group (group 1) (P < 0.01). A statistically significant difference in the percentage of CNV was found among group 3, group 4, and group 5 (P = 0.003). The percentage of CNV in group 4 was significantly higher than that in group 3 and group 5 (P 1 = 0.004; P 2 = 0.006). There was no statistically significant difference in the percentage of CNV between group 3 and group 5 (P = 0.228). Dovitinib is a newly developed multitargeted tyrosine kinase inhibitor. Topical administration of dovitinib effectively inhibited CNV, but this effect of dovitinib was found less than topical bevacizumab.